Dr. Holdener has served as Novimmune's Chairman since 2008. Prior to Novimmune, Eduard served as Global Head of Development and Chief Medical Officer of the Pharma Division at F. Hoffman-La Roche. There he was instrumental in establishing and expanding Roche's therapeutic areas and in achieving several key international approvals for new medicines in oncology, virology, and rheumatology. Before that, Eduard led Roche's development operations in Japan for three years and was a member of the Chugai Co. acquisition and integration team during the Roche/Chugai merger in 2001. He also established a new Roche clinical development center in Shanghai. Eduard holds a medical degree from the University of Zurich and completed a two year fellowship in oncology at the University of Kansas Medical Center in Kansas City. He joined Roche in 1986 after 14 years in academic medicine. Currently, Eduard also serves as a director of Parexel International and HBM Healthcare Investment, two publicly traded companies. He also served as a director of Syntaxin, Cellerix and Tigenix NV.

New medicines in oncology, virology, and rheumatology